Novartis faces a setback in its cholesterol drug development, raising the stakes for Amgen and Eli Lilly in treating Lp(a)…
Read More

Novartis faces a setback in its cholesterol drug development, raising the stakes for Amgen and Eli Lilly in treating Lp(a)…
Read More